Tag Archive for: GSK

British drugmaker GSK on Wednesday warned that the overhaul of laws governing the EU’s pharmaceuticals industry risks forcing companies to invest and innovate elsewhere, which would hurt EU efforts to improve access to medicines.

Hundreds of GSK workers have voted to stage a series of walkouts at UK manufacturing sites in May over a dispute over pay, in what could be a first at the British drugmaker, labour union Unite said on Wednesday.

Tuesday, GSK signed an acquisition agreement with Bellus Health for $2 billion to gain access to the Canadian biotech’s chronic cough candidate camlipixant.

Ghana has become the first country in the world to approve a new malaria vaccine from Oxford University, a potential step forward in fighting a disease that kills hundreds of thousands of children each year.

Antimicrobial resistance (AMR) is a growing threat to global health and was associated with 4.95 million deaths in 2019 globally, more than HIV and malaria combined, as of the WHO’s last readout. Vaccines can be effective tools in combating AMR and have been highlighted by WHO.

In two papers published Wednesday in the New England Journal of Medicine, Pfizer touted positive Phase III data for its respiratory syncytial virus (RSV) vaccine candidate, showing high levels of protection for older adults and infants.

This exclusive licence agreement gives GSK rights to commercialize Brexafemme for vulvovaginal candidiasis and recurrent VVC while continuing to develop ibrexafungerp, which is in phase III clinical trials for the potential treatment of invasive candidiasis (IC), a life-threatening fungal infection.

The company has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur.

Pfizer Inc and GSK are close to bringing the first two vaccines for RSV to the United States after gaining the backing of a panel of advisers to the FDA.

The company is discontinuing the late-stage study of its experimental respiratory syncytial virus adult vaccine, weeks after rivals Pfizer and GSK gained a lead in the race for the first vaccine against the virus.